SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

PolyPid Ltd. (PYPD) News

Follow PolyPid Ltd. (PYPD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol PYPD Asset equity Sector Markets 90 days 6 Last 5.17 Updated Sep 15, 2026, 12:33 PM UTC Open live news feed Open PYPD chart & news
H PolyPid Announces Participation in Upcoming Fall Investor Conferences PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. NASDAQ:PYPD (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effec GEOPOLITICS | Sep 15, 2026, 12:33 PM UTC L PYPD - PolyPid Announces Participation in Upcoming Fall Investor Conferences PYPD - PolyPid Announces Participation in Upcoming Fall Investor Conferences NEWS | Sep 15, 2026, 12:30 PM UTC L PYPD Reports Second Quarter 2026 Financial Results PYPD reports second quarter 2026 financial results and provides corporate update EARNINGS | Aug 12, 2026, 11:30 AM UTC L PYPD - PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 PYPD - PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 EARNINGS | Jul 30, 2026, 12:00 PM UTC L PYPD Polypid announces FDA Acceptance of NDA with priority review for D-plex₁₀₀ Polypid - FDA sets pdufa target action date of November 28, PYPD Polypid announces FDA Acceptance of NDA with priority review for D-plex₁₀₀ Polypid - FDA sets pdufa target action date of November 28, 2026 for D-plex100 - FDA Acceptance triggers $15M milestone payment, completing REGULATION | Jul 29, 2026, 12:30 PM UTC L PYPD Polypid announces exclusive partnership with azurity Pharmaceuticals for the commercialization of D-plex₁₀₀ in the U.S. and Canada Poly PYPD Polypid announces exclusive partnership with azurity Pharmaceuticals for the commercialization of D-plex₁₀₀ in the U.S. and Canada Polypid - to receive over $320M in payments plus tiered royalties - To receive $15M REGULATION | Jul 21, 2026, 11:30 AM UTC